Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | IL1RN | P18510 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29236234 | 0.82 | PTGES2 (0.43) | BCAT1SMN1; SMN2GPR27PTGES2PTPN2 | |
| SCHEMBL28279168 | 0.81 | KMT2A (0.49) | LMNASMN1; SMN2MEN1KMT2APTPN1 | |
| SCHEMBL1649827 | 0.79 | CA2 (0.47) | LMNASMN1; SMN2KEAP1HPGDHSD17B10 | |
| SCHEMBL8764610 | 0.75 | CCR2 (0.44) | SMN1; SMN2PTPN1HPGDCA2CA12 | |
| SCHEMBL10823736 | 0.74 | NPC1 (0.54) | LMNASMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL28643561 | 0.72 | CYP2A6 (0.47) | LMNASMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL18672576 | 0.71 | CCR2 (0.75) | — | |
| SCHEMBL28607455 | 0.71 | PKM (0.67) | LMNASMN1; SMN2MEN1KMT2APTPN2 | |
| SCHEMBL7577515 | 0.71 | SMN1; SMN2 (0.65) | LMNASMN1; SMN2IL1RNKEAP1ERAP1 | |
| SCHEMBL7267146 | 0.70 | CA2 (0.62) | BCAT1ERAP1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334713-B1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10975051-B2 | Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975051-B2 | Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975051-B2 | Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-04-13 | — | — | US | disclosed |
| US-20180237406-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180237406-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180237407-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180237407-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-08-23 | — | — | US | disclosed |
| CN-108349924-A | Benzenesulfonamido--benzofuran derivatives and application thereof | 纪念斯隆凯特林癌症中心 | 2018-07-31 | — | — | CN | disclosed |
| CN-108349924-A | Benzenesulfonamido--benzofuran derivatives and application thereof | 纪念斯隆凯特林癌症中心 | 2018-07-31 | — | — | CN | disclosed |
| CN-108349924-A | Benzenesulfonamido--benzofuran derivatives and application thereof | 纪念斯隆凯特林癌症中心 | 2018-07-31 | — | — | CN | disclosed |
| EP-3334713-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | Memorial Sloan Kettering Cancer Center (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3334713-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | Memorial Sloan Kettering Cancer Center (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027845-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027845-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027841-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027841-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975051-B2 | Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases | BCL2L1, BCL2, BCLAF1 | BCAT1 2060/4885LMNA 2043/4885SMN1; SMN2 943/4885 |
| US-20180237407-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | BCL2L1, BCL2, BCLAF1 | BCAT1 2060/4885LMNA 2043/4885SMN1; SMN2 943/4885 |
| US-20180237406-A1 | PHENYLSULFONAMIDO-BENZOFURAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES | BCL2L1, BCL2, BCLAF1 | BCAT1 2060/4885LMNA 2043/4885SMN1; SMN2 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.